20 articles
Breakthrough study reveals sepiapterin dramatically outperforms existing PKU therapy, offering hope for better metabolic control.
A Phase IIa trial explores whether the HIF-PHI drug daprodustat can safely replace EPO injections in hemodialysis patients with anemia.
A 2025 mini-review synthesizes RCTs and meta-analyses showing hypertonic dextrose prolotherapy rivals or beats standard OA injections.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
FDA approval of the first T1D delay drug nearly doubled islet autoantibody testing, but critical gaps remain in screening healthy children.
Researchers explore targeted immune strategies to improve pancreatic islet transplant success rates for diabetes treatment.
A completed Maastricht trial tests whether targeted protein and exercise can boost muscle protein synthesis before dialysis becomes necessary.
A Phase 2 trial tests a GalNAc-conjugated antisense therapy in familial partial lipodystrophy patients with dangerously high triglycerides.
Researchers shift from systemic B-cell targeting to localized immune control, potentially improving transplant success rates.
New research reveals pulsed electromagnetic field therapy selectively enhances ATP-linked mitochondrial respiration, pointing to a specific cellular energy mechanism.
Stanford study tests whether GLP-1 drug exenatide can restore insulin function and promote weight loss in people with prediabetes.
Eli Lilly's phase 3 trial pits a novel weekly basal insulin against the gold-standard daily insulin degludec in type 1 diabetes patients.
Weekly tirzepatide injections led to up to 22% weight loss in Japanese participants, with 96-100% achieving clinically significant results.
A dual-action therapy combining a glucose-responsive hydrogel with stem cell exosomes dramatically speeds diabetic wound closure in mice.
A completed RCT tests whether small-sided football sessions 3x/week improve glucose control and metabolic health in T2DM patients on GLP-1 and SGLT2 drugs.
A landmark 9,000-patient trial finds balanced crystalloids and normal saline perform equally for children in septic shock.
Takeda's Phase 1 trial evaluates the safety and tolerability of TAK-510, a novel injectable agent targeting nausea and vomiting, across escalating doses.
A landmark JCI review maps the expanding pharmacological arsenal for MASH, from GLP-1 agonists to triple receptor therapies and precision medicine.
New research reveals how blood vessel maturity around transplanted insulin-producing cells determines long-term survival.
A newly identified protein shields the liver from alcohol injury by bridging mitochondria and fat droplets to enhance fatty acid oxidation.
